Acticor Biotech
ALACT | PA
Overview
Corporate Details
- ISIN(s):
- FR0012519668 (+1 more)
- LEI:
- 969500K433EK1G89EV95
- Country:
- France
- Address:
- 82 AVENUE DU MAINE, 75014 PARIS
- Website:
- https://www.acticor-biotech.com
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Acticor Biotech is a clinical-stage biopharmaceutical company specializing in the research and development of medicines for thrombotic diseases. A spin-off from the French National Institute of Health and Medical Research (INSERM), the company's primary focus is on treating cardiovascular emergencies, particularly the acute phase of ischemic stroke. Its lead drug candidate, glenzocimab, is a 'first-in-class' innovative treatment designed to be administered shortly after the onset of stroke symptoms to limit sequelae. The company also explores the application of its therapeutic approach to other conditions, such as pulmonary embolism.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Acticor Biotech.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-01-06 08:00 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 171.0 KB | |
| 2025-01-06 08:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 169.3 KB | |
| 2024-12-19 18:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 205.7 KB | |
| 2024-12-19 18:00 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 214.6 KB | |
| 2024-12-10 18:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 202.1 KB | |
| 2024-12-10 18:00 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 214.1 KB | |
| 2024-11-06 08:30 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 177.1 KB | |
| 2024-11-06 08:30 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 179.2 KB | |
| 2024-11-04 11:46 |
Earnings Release
Inside Information / News release on accounts, results
|
English | 322.8 KB | |
| 2024-11-04 11:46 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 311.2 KB | |
| 2024-10-31 17:45 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 400.7 KB | |
| 2024-10-31 17:45 |
Interim Report
Inside Information / News release on accounts, results
|
English | 464.4 KB | |
| 2024-10-16 17:45 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 289.1 KB | |
| 2024-10-16 17:45 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 223.1 KB | |
| 2024-10-14 08:00 |
Board/Management Information
Informations privilégiées / Autres communiqués
|
French | 275.7 KB |
Automate Your Workflow. Get a real-time feed of all Acticor Biotech filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Acticor Biotech via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
